DOI QR코드

DOI QR Code

Screening for Colorectal Neoplasias with Fecal Occult Blood Tests: False-positive Impact of Non-Dietary Restriction

  • Published : 2012.01.31

Abstract

Objective: Screening for colorectal cancer using guaiac-based fecal occult blood tests (gFOBT) is well established in Western populations, but is hampered by poor patient compliance due to the imposed dietary restrictions. Fecal immunochemical tests (FIT) do not require dietary restriction, but are more expensive than gFOBT and therefore restrict its use in developing countries in Asia. However, Asian diets being low in meat content may not require diet restriction for gFOBT to achieve equivalent results. The objective of this study was to evaluate and compare the validity and suitability of gFOBT and FIT or a combination of the two in screening for colorectal neoplasias without prior dietary restriction in an Asian population. Methods: Patients referred to the Endoscopic Unit for colonoscopy were recruited for the study. Stool samples were collected prior to bowel preparation, and tested for occult blood with both gFOBT and FIT. Dietary restriction was not imposed. To assess the validity of either tests or in combination to detect a neoplasm or cancer in the colon, their false positive rates, their sensitivity (true positive rate) and the specificity (true negative rate) were analyzed and compared. Results: One hundred and three patients were analysed. The sensitivity for picking up any neoplasia was 53% for FIT, 40% for gFOBT and 23.3% for the combination. The sensitivities for picking up only carcinoma were 77.8%, 66.7% and 55.5%, respectively. The specificity for excluding any neoplasia was 91.7% for FIT, 74% for gFOBT and 94.5% for a combination, whereas for excluding only carcinomas they were 84%, 73.4% and 93.6%. Of the 69 with normal colonoscopic findings, FOBT was positive in 4.3%, 23.2 %and 2.9% for FIT, gFOBT, or combination of tests respectively. Conclusion: FIT is the recommended method if we are to dispense with dietary restriction in our patients because of its relatively low-false positivity and better sensitivity and specificity rates.

Keywords

References

  1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996). A comparison of fecal occult-blood tests for colorectal-cancer screening. New Engl J Med, 334, 155-9. https://doi.org/10.1056/NEJM199601183340304
  2. Ciccolallo L, Capocaccia R, Coleman MP, et al (2005). Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery, Gut, 54, 268-73. https://doi.org/10.1136/gut.2004.044214
  3. Cole SR, Young GP, Esterman A, Cadd B, Morcom J (2003). A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen, 10, 117-22. https://doi.org/10.1258/096914103769011003
  4. Collins JF, Lieberman DA, Durbin TE, et al (2005). Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Int Med, 142, 81-85. https://doi.org/10.7326/0003-4819-142-2-200501180-00006
  5. Espey DK, Wu XC, Swan J, et al (2007). Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska natives. Cancer, 110, 2119-52. https://doi.org/10.1002/cncr.23044
  6. Gatta G, Ciccolallo L, Capocaccia R, et al (2003). Differences in colorectal cancer survival between European and Us Populations: the importance of sub-site and morphology. Eur J Cancer, 39, 2214-22. https://doi.org/10.1016/S0959-8049(03)00549-5
  7. Gopalswamy N, Stelling HP, Markert RJ, et al (1994). A comparative study of eight fecal occult blood tests and HemoQuant in patients in whom colonoscopy is indicated. Arch Fam Med, 3, 1043-8. https://doi.org/10.1001/archfami.3.12.1043
  8. Greenberg PD, Bertario L, Gnauck R, et al (2000). A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol, 95, 1331-8. https://doi.org/10.1111/j.1572-0241.2000.02032.x
  9. Greenlee RT, Hill-Harmon MB, Murray T, Bolden S, Wingo PA (2001). Cancer statistics. CA Cancer J Clin, 51, 15-36. https://doi.org/10.3322/canjclin.51.1.15
  10. Hardcastle JD, Thomas WM, Chamberlain J, et al (1989). Randomised controlled trial of faecal occult blood screening for colorectal cancer: Results for first 107,349 Subjects. Lancet, 333, 1160-4. https://doi.org/10.1016/S0140-6736(89)92750-5
  11. Hardcastle JD, Robinson MH, Moss SM, et al (1996). Randomised controlled trial of faecaloccult-blood screening for colorectal cancer. Lancet, 348, 1472-1477. https://doi.org/10.1016/S0140-6736(96)03386-7
  12. Kong CK, RoslaniAC, Law CW, Law SKD, Arumugam K (2010). Impact of socio-economic class on colorectal cancer patient outcomes in Kuala Lumpur and Kuching, Malaysia. Asian Pacific J Cancer Prev, 11, 969-74.
  13. Kronborg O, Fenger C, Worm J, et al (1996). Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet, 348, 1467-71. https://doi.org/10.1016/S0140-6736(96)03430-7
  14. Landis SH, Murray T, Bolden S,Wingo PA (1998). Cancer statistics, 1998. CA Cancer J Clin, 48, 6-2 9. https://doi.org/10.3322/canjclin.48.1.6
  15. Levi, Z., Rozen, et al (2007). A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Int Med, 146, 244-55. https://doi.org/10.7326/0003-4819-146-4-200702200-00003
  16. Mandel JS, Bond JS, Church TR, et al (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med, 328, 1365-71. https://doi.org/10.1056/NEJM199305133281901
  17. Ministry of Health Malaysia. (2006). Malaysia Cancer Staistics, Extracted from http://www.moh.gov.
  18. Morikawa, T, Kato J, Yamaji Y, et al (2005). A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology, 129, 422-8. https://doi.org/10.1016/j.gastro.2005.05.056
  19. Silverman AL, Desai TK, Dhar R (1988). Clinical features, evaluation, and detection of colorectal cancer. Gastroenterol Clin North Am, 17, 713-725.

Cited by

  1. Prevalence and Characteristics of Colorectal Polyps in Symptomatic and Asymptomatic Iranian Patients Undergoing Colonoscopy from 2009-2013 vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9933
  2. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening vol.64, pp.1, 2015, https://doi.org/10.1136/gutjnl-2013-306503
  3. Factors associated with false-positive fecal immunochemical tests in a large German colorectal cancer screening study pp.00207136, 2019, https://doi.org/10.1002/ijc.31972